Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception
There are two injectable progestogen-only contraceptives (IPCs) that have been available in many countries in the world since 1983. They are both still extensively used in many developing countries, forming a large proportion of the health system's expenditure on contraception. These are depot...
Saved in:
Published in | Cochrane database of systematic reviews no. 3; p. CD005214 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
19.07.2006
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | There are two injectable progestogen-only contraceptives (IPCs) that have been available in many countries in the world since 1983. They are both still extensively used in many developing countries, forming a large proportion of the health system's expenditure on contraception. These are depot medroxyprogesterone acetate (DMPA) and norethisterone oenanthate (NET-EN). These are both highly effective contraceptives that receive wide acceptance amongst women in their fertile years. They differ in frequency of administration that has implications on patient uptake. They also differ in cost that may significantly affect budgeting in the health system. A systematic comparison will aid to ensure their rational use.
To determine if there are differences between depot medroxyprogesterone acetate given at a dose of 150 mg IM every 3 months and norethisterone oenanthate given at a dose of 200mg IM every 2 months, in terms of contraceptive effectiveness, reversibility and discontinuation patterns, minor effects and major effects.
We searched the computerized databases MEDLINE using PubMed, Popline, Cochrane Controlled Trials Register, Biblioline, LILACS, EMBASE and PASCAL for randomised controlled trials of DMPA versus NET-EN for long-acting progestogenic contraception. Studies were included regardless of language, and all databases were reviewed from the time that injectable progestogens have been in use.
All randomised controlled comparisons of DMPA acetate given at a dose of 150 mg IM every 3 months versus NET-EN given at a dose of 200mg IM every 2 months, used for contraception, were included. Trials had to report on contraceptive efficiency and return to fertility, discontinuation risks and reasons for discontinuation, and clinical effects, both menstrual and non-menstrual.
BD and CM evaluated the titles and abstracts obtained through applying the search strategy and applied the eligibility criteria. BD attempted to contact authors where clarification of the data was required, and contacted all main manufacturers of the contraceptives. After inclusion of the two studies, the data was abstracted and analysed with RevMan 4.2.
Two trials were included in this review. There was no significant difference between the two treatment groups for the frequency of discontinuation for either contraceptive, although the women on NET-EN were 4% more likely to discontinue for personal reasons than those on DPMA. Discontinuation because of accidental pregnancy did not differ between the groups. Although the duration of bleeding and spotting events was the same in each group, women on DPMA were 21% more likely to develop amenorrhoea. Mean changes in body weight at 12 and 24 months, and in systolic and diastolic blood pressure at 12 months did not differ significantly between the studies.
While the choice between DPMA and NET-EN as injectable progestogen contraceptives may vary between both health providers and patients, data from randomized controlled trials indicate little difference between the effects of these methods, except that women on DMPA are more likely to develop amenorrhoea. There is inadequate data to detect differences in some non-menstrual major and minor clinical effects. |
---|---|
AbstractList | There are two injectable progestogen-only contraceptives (IPCs) that have been available in many countries in the world since 1983. They are both still extensively used in many developing countries, forming a large proportion of the health system's expenditure on contraception. These are depot medroxyprogesterone acetate (DMPA) and norethisterone oenanthate (NET-EN). These are both highly effective contraceptives that receive wide acceptance amongst women in their fertile years. They differ in frequency of administration that has implications on patient uptake. They also differ in cost that may significantly affect budgeting in the health system. A systematic comparison will aid to ensure their rational use.
To determine if there are differences between depot medroxyprogesterone acetate given at a dose of 150 mg IM every 3 months and norethisterone oenanthate given at a dose of 200mg IM every 2 months, in terms of contraceptive effectiveness, reversibility and discontinuation patterns, minor effects and major effects.
We searched the computerized databases MEDLINE using PubMed, Popline, Cochrane Controlled Trials Register, Biblioline, LILACS, EMBASE and PASCAL for randomised controlled trials of DMPA versus NET-EN for long-acting progestogenic contraception. Studies were included regardless of language, and all databases were reviewed from the time that injectable progestogens have been in use.
All randomised controlled comparisons of DMPA acetate given at a dose of 150 mg IM every 3 months versus NET-EN given at a dose of 200mg IM every 2 months, used for contraception, were included. Trials had to report on contraceptive efficiency and return to fertility, discontinuation risks and reasons for discontinuation, and clinical effects, both menstrual and non-menstrual.
BD and CM evaluated the titles and abstracts obtained through applying the search strategy and applied the eligibility criteria. BD attempted to contact authors where clarification of the data was required, and contacted all main manufacturers of the contraceptives. After inclusion of the two studies, the data was abstracted and analysed with RevMan 4.2.
Two trials were included in this review. There was no significant difference between the two treatment groups for the frequency of discontinuation for either contraceptive, although the women on NET-EN were 4% more likely to discontinue for personal reasons than those on DPMA. Discontinuation because of accidental pregnancy did not differ between the groups. Although the duration of bleeding and spotting events was the same in each group, women on DPMA were 21% more likely to develop amenorrhoea. Mean changes in body weight at 12 and 24 months, and in systolic and diastolic blood pressure at 12 months did not differ significantly between the studies.
While the choice between DPMA and NET-EN as injectable progestogen contraceptives may vary between both health providers and patients, data from randomized controlled trials indicate little difference between the effects of these methods, except that women on DMPA are more likely to develop amenorrhoea. There is inadequate data to detect differences in some non-menstrual major and minor clinical effects. |
Author | Morroni, C Draper, B H Smit, J Hoffman, M Van der Merwe, L Hapgood, J Beksinska, M |
Author_xml | – sequence: 1 givenname: B H surname: Draper fullname: Draper, B H email: bevdraper@iafrica.com organization: University of Cape Town, Public Health and Family Medicine, Faculty of Health Sciences, Faculty of Health Sciences, Anzio Road, Observatory, Cape Town, South Africa 7925. bevdraper@iafrica.com – sequence: 2 givenname: C surname: Morroni fullname: Morroni, C – sequence: 3 givenname: M surname: Hoffman fullname: Hoffman, M – sequence: 4 givenname: J surname: Smit fullname: Smit, J – sequence: 5 givenname: M surname: Beksinska fullname: Beksinska, M – sequence: 6 givenname: J surname: Hapgood fullname: Hapgood, J – sequence: 7 givenname: L surname: Van der Merwe fullname: Van der Merwe, L |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16856087$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kNtKAzEURYMo9qK_UPIDM-be5FFab1DwRcG3kmSS6UibDEkq9u8N2L6cDXuzz2GdGbgOMTgAFhi1GCHygJngWHLZrtYIcYJZOx4NuQLTGqiGKfo1AbOcvxGiCmN5CyZYSC6QXE6BX7sxFnhwXYq_pzHF3uXiUj0Af1zKxwxDTK7shosbXdCh7HRx0McE9zH0jbZlCD08t-sIg4U2hpK0dWMZYrgDN17vs7s_6xx8Pj99rF6bzfvL2-px01jKGWmM91LyzhluKGJcdJR7TiwR1RaUYtwZzZRHimnDkbRedEureGcpUqLikTlY_O-tH6hM2zENB51O2wsw-QNycF0T |
CitedBy_id | crossref_primary_10_1136_jfprhc_2015_101334 crossref_primary_10_1016_j_contraception_2018_12_001 crossref_primary_10_1016_j_bpobgyn_2010_02_017 crossref_primary_10_1186_s12960_022_00763_8 crossref_primary_10_1016_j_bpobgyn_2010_04_005 crossref_primary_10_1016_S0140_6736_12_61127_1 crossref_primary_10_1371_journal_pone_0062895 crossref_primary_10_1016_S2352_3018_15_00076_4 crossref_primary_10_1111_hiv_12247 crossref_primary_10_1210_er_2017_00103 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1002/14651858.CD005214.pub2 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1469-493X |
ExternalDocumentID | 16856087 |
Genre | Systematic Review Journal Article Review |
GroupedDBID | --- 53G 5GY 7PX 9HA ABJNI ACGFO ACGFS AENEX ALMA_UNASSIGNED_HOLDINGS ALUQN AYR CGR CUY CVF D7G ECM EIF HYE NPM OEC OK1 P2P RWY WOW ZYTZH |
ID | FETCH-LOGICAL-c3542-bff885deb5b30456d35f52c26f8863311dba49f094ab508cf6d7c95dc30960032 |
IngestDate | Wed Jul 24 02:33:21 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3542-bff885deb5b30456d35f52c26f8863311dba49f094ab508cf6d7c95dc30960032 |
OpenAccessLink | https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005214.pub2 |
PMID | 16856087 |
ParticipantIDs | pubmed_primary_16856087 |
PublicationCentury | 2000 |
PublicationDate | 20060719 |
PublicationDateYYYYMMDD | 2006-07-19 |
PublicationDate_xml | – month: 7 year: 2006 text: 20060719 day: 19 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Cochrane database of systematic reviews |
PublicationTitleAlternate | Cochrane Database Syst Rev |
PublicationYear | 2006 |
SSID | ssj0039118 |
Score | 1.9955418 |
SecondaryResourceType | review_article |
Snippet | There are two injectable progestogen-only contraceptives (IPCs) that have been available in many countries in the world since 1983. They are both still... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | CD005214 |
SubjectTerms | Contraception - methods Contraceptive Agents, Female - administration & dosage Delayed-Action Preparations - administration & dosage Drug Administration Schedule Female Humans Medroxyprogesterone Acetate - administration & dosage Norethindrone - administration & dosage Norethindrone - analogs & derivatives Randomized Controlled Trials as Topic |
Title | Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception |
URI | https://www.ncbi.nlm.nih.gov/pubmed/16856087 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NT9swFLcKSIjLBGwwBpt84IYMSfwR54jaTdWkcgKJG4rtGJBGU6Husvv-b96zkyUtBTEuVmQnVpT3y_vy-yDk2KW5cV4oZkpumRDCMC0MWCm85EmVWcs5ZiNPLtT4Svy8lteDwd9e1NLvuTm1f1bmlbyHqjAHdMUs2f-g7L9NYQKugb4wAoVhfBONR6A9z_F4HGNRMNIqlD2oQW_EYAssvYpJilhSOM7WFYa93IF6GaILf9XTW4aJDSEhPTwNA3bECQHsZRPx0tdfh7W9A-lWnWBkKUpAVDaXq0F3evoIc7uiP6DLgpjUj1iQd8FFO669b3yxXYPjh_vewVXPM5Gzhv9VkZuC7c1EERr-tkDiPW45HKFXOiaRPmPlsTRsir3atdSn7b0I06z_AJBk9hAInCoN-luU36-vLpXYbpfWyFqukU1eoMsninMO0kC3qeVJdrb6hbD2bLPJkn0S9JTLbfKhMTDoeUTLDhlU012yOWlCKD4SH0BDV4CGRtDQRdDQDjQUQEN7oKELoKELoPlErn58vxyOWdNsg1kuRcaM91pLVxlp8PBcOS69zGymYFpxnqbOlKLwSSFKA0q99crltpDOcjSCE57tkfUpvNVnQqXwshRwaylgJ6d0BUa1tqXyuStE4g_IfvxCN7NYUeWm_XZfXlw5JFsdxI7IhodfuPoK-uDcfAv0egIVvmRx |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Depot+medroxyprogesterone+versus+norethisterone+oenanthate+for+long-acting+progestogenic+contraception&rft.jtitle=Cochrane+database+of+systematic+reviews&rft.au=Draper%2C+B+H&rft.au=Morroni%2C+C&rft.au=Hoffman%2C+M&rft.au=Smit%2C+J&rft.date=2006-07-19&rft.eissn=1469-493X&rft.issue=3&rft.spage=CD005214&rft_id=info:doi/10.1002%2F14651858.CD005214.pub2&rft_id=info%3Apmid%2F16856087&rft_id=info%3Apmid%2F16856087&rft.externalDocID=16856087 |